
Surprise! Despite Covid-19 sales, Indian pharma an underperformer
A majority of pharma stocks reported double digit negative returns, while the overall market (BSE Sensex) delivered a 9% plus return.
A majority of pharma stocks reported double digit negative returns, while the overall market (BSE Sensex) delivered a 9% plus return.
Home-grown smaller players are giving biggies a run for their money in the US generics market.
The problems faced by FDA’s investigators in India are similar to those around the world, US Food and Drug Administration spokesperson Jeremy Kahn tells Fortune India.